Stock listing
LSE:0HI3 Arrowhead Pharmaceuticals, Inc. Share Price
UK listing (LSE) of Arrowhead Pharmaceuticals, Inc. · home listing NASDAQ:ARWR
Follow Arrowhead Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · LSE:0HI3
$42.35 USD -0.92 (-2.1%)
Close on Nov 20, 2026
- Day range
- $42.35 – $44.58 USDNov 20, 2026
- Volume
- 1,376 sharesNov 20, 2026
- 52-week range
- $37.44 – $95.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $84,641 USDMedian day 564 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ARWR · Home | $41.37 USD | -1.74 (-4.0%) | 3,906,214 | $43.42 | $44.80 | $41.17 | $43.11 | Close on Nov 20, 2026 |
| B3:A2RR34 | 30.84 BRL | -0.78 (-2.5%) | — | 30.84 | 30.84 | 30.84 | 31.62 | Close on Nov 19, 2026 |
| LSE:0HI3 | $42.35 USD | -0.92 (-2.1%) | 1,376 | $43.50 | $44.58 | $42.35 | $43.27 | Close on Nov 20, 2026 |
| Frankfurt:HDP1 | €37.74 EUR | -1.94 (-4.9%) | — | €39.51 | €39.51 | €37.74 | €39.68 | Close on Nov 20, 2026 |
| Munich:HDP1 | €39.47 EUR | -0.29 (-0.7%) | — | €39.47 | €39.47 | €39.47 | €39.76 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · LSE:0HI3 · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $57.45 | -0.67 | -1.2% | $59.01 | $59.01 | $57.39 | 114 | |
| $58.12 | -3.65 | -5.9% | $60.42 | $62.00 | $57.92 | 3,148 | |
| $61.77 | +1.66 | +2.8% | $61.83 | $62.00 | $59.29 | 380 | |
| $60.11 | +0.52 | +0.9% | $59.55 | $60.59 | $59.19 | 61 | |
| $59.59 | +0.61 | +1.0% | $61.00 | $61.02 | $59.59 | 245 | |
| $58.98 | -1.03 | -1.7% | $59.52 | $61.00 | $58.72 | 349 | |
| $60.01 | +0.64 | +1.1% | $60.21 | $62.00 | $59.93 | 1,658 | |
| $59.37 | -0.568 | -0.9% | $60.20 | $60.20 | $58.29 | 1,309 | |
| $59.94 | +0.618 | +1.0% | $59.48 | $60.38 | $57.67 | 270 | |
| $59.32 | +1.40 | +2.4% | $58.25 | $59.35 | $57.40 | 306 | |
| $57.92 | +0.24 | +0.4% | $57.90 | $58.50 | $56.62 | 102 | |
| $57.68 | -2.08 | -3.5% | $57.99 | $59.35 | $57.68 | 1,925 | |
| $59.76 | +1.176 | +2.0% | $59.96 | $60.08 | $58.90 | 136 | |
| $58.58 | +1.734 | +3.1% | $56.50 | $59.43 | $56.50 | 78 | |
| $56.85 | +0.53 | +0.9% | $56.05 | $57.50 | $56.05 | 169 | |
| $56.32 | -1.54 | -2.7% | $58.50 | $59.20 | $55.92 | 8,168 | |
| $57.86 | -1.108 | -1.9% | $58.50 | $59.42 | $57.74 | 1,225 | |
| $58.97 | +0.118 | +0.2% | $57.91 | $63.49 | $57.31 | 9,084 | |
| $58.85 | -1.801 | -3.0% | $61.00 | $61.00 | $58.21 | 1,004 | |
| $60.65 | -1.709 | -2.7% | $64.50 | $64.50 | $60.65 | 883 | |
| $62.36 | +1.94 | +3.2% | $61.25 | $62.73 | $61.10 | 703 | |
| $60.42 | -1.01 | -1.6% | $60.62 | $60.86 | $59.44 | 1,017 | |
| $61.43 | -0.51 | -0.8% | $60.50 | $62.05 | $60.50 | 71 | |
| $61.94 | -1.29 | -2.0% | $62.35 | $63.40 | $60.69 | 707 | |
| $63.23 | -1.429 | -2.2% | $65.15 | $65.15 | $62.56 | 493 | |
| $64.66 | -0.421 | -0.6% | $63.00 | $66.16 | $63.00 | 644 | |
| $65.08 | -1.01 | -1.5% | $65.30 | $67.24 | $64.80 | 454 | |
| $66.09 | +0.32 | +0.5% | $65.13 | $66.96 | $65.13 | 361 | |
| $65.77 | -0.05 | -0.1% | $66.00 | $66.07 | $64.83 | 47 | |
| $65.82 | +0.07 | +0.1% | $66.00 | $66.23 | $64.08 | 569 | |
| $65.75 | -0.249 | -0.4% | $66.58 | $66.68 | $65.63 | 269 | |
| $66.00 | -0.60 | -0.9% | $66.90 | $68.00 | $65.66 | 504 | |
| $66.60 | -5.16 | -7.2% | $71.87 | $73.50 | $66.36 | 1,829 | |
| $71.76 | +3.79 | +5.6% | $71.00 | $71.97 | $68.10 | 1,146 | |
| $67.97 | +1.19 | +1.8% | $67.50 | $68.62 | $65.51 | 1,838 | |
| $66.78 | -0.70 | -1.0% | $67.82 | $68.89 | $66.78 | 558 | |
| $67.48 | +0.41 | +0.6% | $66.43 | $68.64 | $66.43 | 1,105 | |
| $67.07 | -5.67 | -7.8% | $72.00 | $72.00 | $66.53 | 1,832 | |
| $72.74 | -8.00 | -9.9% | $81.50 | $83.21 | $72.67 | 1,308 | |
| $80.74 | -3.73 | -4.4% | $81.50 | $84.00 | $80.74 | 194 | |
| $84.47 | +1.53 | +1.8% | $83.75 | $86.01 | $82.71 | 440 | |
| $82.94 | -0.61 | -0.7% | $81.00 | $83.36 | $80.15 | 56 | |
| $83.55 | -2.56 | -3.0% | $84.65 | $87.03 | $83.55 | 3,701 | |
| $86.11 | +1.88 | +2.2% | $85.65 | $86.90 | $83.55 | 3,865 | |
| $84.23 | -1.03 | -1.2% | $86.25 | $86.50 | $84.23 | 56 | |
| $85.26 | +1.85 | +2.2% | $85.23 | $86.22 | $83.89 | 173 | |
| $83.41 | +0.596 | +0.7% | $81.50 | $85.14 | $81.50 | 646 | |
| $82.81 | +1.784 | +2.2% | $81.47 | $83.07 | $80.00 | 1,849 | |
| $81.03 | -4.02 | -4.7% | $85.41 | $88.07 | $81.03 | 2,964 | |
| $85.05 | -3.85 | -4.3% | $90.00 | $90.00 | $84.46 | 735 | |
| $88.90 | -0.45 | -0.5% | $90.00 | $90.00 | $88.16 | 199 | |
| $89.35 | +0.63 | +0.7% | $89.13 | $89.99 | $86.80 | 463 | |
| $88.72 | +2.19 | +2.5% | $86.00 | $90.08 | $86.00 | 3,975 | |
| $86.53 | +0.37 | +0.4% | $88.00 | $88.35 | $85.69 | 2,763 | |
| $86.16 | -0.56 | -0.6% | $86.55 | $87.65 | $86.06 | 233 | |
| $86.72 | -2.17 | -2.4% | $90.50 | $90.50 | $86.06 | 329 |
- Ticker
- LSE:0HI3
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Latest earnings call · Nov 12, 2026
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2026 Earnings Call
Replay and transcript
Latest deck · Oct 14, 2026
Technical Presentation (October 2026)
Technical · 47 slides
Latest news
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 17, 2026
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
Nov 4, 2026
Closed $61.77 (+2.8%) on Nov 4, 2026
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
Nov 3, 2026
Closed $61.77 (+2.8%) on Nov 4, 2026
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Nov 2, 2026
Closed $59.59 (+1.0%) on Nov 2, 2026
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Oct 27, 2026
Closed $59.94 (+1.0%) on Oct 27, 2026
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Oct 14, 2026
Closed $58.97 (+0.2%) on Oct 14, 2026
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Oct 7, 2026
Closed $61.43 (-0.8%) on Oct 7, 2026
Arrowhead Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 55 in the last 12 months · 292 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 12, 2026
- Decks
- 16 decks · latest Oct 14, 2026
Where Arrowhead Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ARWR · Home listing | NASDAQ | United States | USD |
| gettex:HDP1 | gettex | Germany | EUR |
| B3:A2RR34 | B3 | Brazil | BRL |
| LS Exchange:A2AGYB | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AGYB | Lang & Schwarz | Germany | EUR |
| BMV:ARWR | BMV | Mexico | MXN |
| LSE:0HI3 · This page | LSE | United Kingdom | USD |
| BOATS:ARWR | BOATS | United States | USD |
| Tradegate:HDP1 | Tradegate | Germany | EUR |
| Frankfurt:HDP1 | Frankfurt | Germany | EUR |
| Stuttgart:HDP1 | Stuttgart | Germany | EUR |
| BIVA:ARWR | BIVA | Mexico | MXN |
| BX Swiss:HDP1 | BX Swiss | Switzerland | CHF |
| Dusseldorf:HDP1 | Dusseldorf | Germany | EUR |
| Hamburg:HDP1 | Hamburg | Germany | EUR |
| Munich:HDP1 | Munich | Germany | EUR |
| Hanover:HDP1 | Hanover | Germany | EUR |
| Xetra:HDP1 | Xetra | Germany | EUR |
Valuation
EV/sales 10.3× against a median of 33.4×: 2nd lowest of 6 Biotechnology companies shown. Statements: Year to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.66B USD
- P/E
- Loss
- EV/sales
- 10.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 116×
- Gross margin
- Not reported
- Operating margin
- −156.9%
- Net margin
- −160.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.34
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR | US$5.85B | US$4.66B | n/a | 10.3× | n/a | 116× | −160.6% | 0.0× | 1.34 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Belite Bio, Inc. · NASDAQ:BLTE | US$5.13B | US$5.13B | n/a | n/a | n/a | 6.6× | n/a | 0.0× | 1.34 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.05B | US$4.77B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Median of the others | US$6.20B | US$5.63B | 16.9× | 33.4× | 20.1× | 6.7× | −36.4% | 0.0× | 1.34 |
Forecasts
10 strong buy · 4 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 105.86 USD · Analysts' mean
- EPS, year to Sep 2027
- -5.56 · 10 analysts
- Revenue, year to Sep 2027
- 310.5M · 15 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Christopher Anzalone | President, CEO and Chairman of the Board |
| Daniel Apel | Chief Financial Officer |
| Patrick O’Brien | Chief Operating Officer |
| James Hamilton | Chief Medical Officer, Head of R&D |
| Tao Pei | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Christopher Anzalone | President, CEO and Chairman of the Board |
| Hongbo Lu | |
| Matt Cohen | Board Member |
| Mauro Ferrari | |
| Michael Perry | |
| Oye Olukotun | |
| Victoria Vakiener | |
| William Waddill |
Events
Calls
| Call | When | Status |
|---|---|---|
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2026 Earnings Call | Thu, Nov 12, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2026 Earnings Call | Thu, Feb 05, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2025 Earnings Call | Tue, Nov 25, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2025 Earnings Call | Mon, May 12, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2025 Earnings Call | Mon, Feb 10, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2024 Earnings Call | Tue, Nov 26, 2024 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2026 | Nov 12, 2026 · After close | +1.3% |
| Q3 2026 | Aug 4, 2026 · After close | −3.0% |
| Q2 2026 | May 7, 2026 · After close | −6.8% |
| Q1 2026 | Feb 5, 2026 · After close | −0.2% |
| Q4 2025 | Nov 25, 2025 | +30.4% |
| Q3 2025 | Aug 7, 2025 · After close | +2.2% |
| Q2 2025 | May 12, 2025 · After close | +9.4% |
| Q1 2025 | Feb 10, 2025 · After close | −5.2% |
| Q4 2024 | Nov 27, 2024 · Before open | +24.2% |
| Q3 2024 | Aug 8, 2024 · After close | −9.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | May 9, 2024 · After close | −10.7% |
| Q1 2024 | Feb 6, 2024 · After close | −4.7% |
| Q4 2023 | Nov 29, 2023 · After close | −26.9% |
| Q3 2023 | Aug 7, 2023 · After close | −10.8% |
| Q2 2023 | May 2, 2023 · After close | +13.6% |
| Q1 2023 | Feb 6, 2023 · After close | +0.3% |
| Q4 2022 | Nov 28, 2022 · After close | +7.1% |
| Q3 2022 | Aug 4, 2022 · After close | −0.4% |
| Q2 2022 | May 10, 2022 · After close | −15.6% |
| Q1 2022 | Feb 2, 2022 · After close | −6.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2026) | Technical | 47 slides | Oct 14, 2026 |
| Technical Presentation (June 2026) | Technical | 57 slides | Jun 29, 2026 |
| Technical Presentation (January 2026) | Technical | 65 slides | Jan 6, 2026 |
| TIDES USA 2026 | Conference | 26 slides | 2026 |
| Investor Presentation (December 2025) | Investor deck | 38 slides | December 2025 |
| Corporate Update (November 2025) | Corporate update | 43 slides | Nov 18, 2025 |
| RNA Leaders USA Congress 2025 | Conference | 25 slides | Sep 10, 2025 |
| Complement Based Drug Development Summit 2024 | Conference | 20 slides | Dec 11, 2024 |
| Technical Presentation (October 2024) | Technical | 68 slides | Oct 7, 2024 |
| American Heart Association Scientific Sessions 2023 | Conference | 14 slides | 2023 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (2022) | Technical | 11 slides | 2022 |
| Arrowhead Research — Investor Presentation (April 2009) | Investor deck | 14 slides | Apr 3, 2009 |
| Arrowhead Research — Investor Presentation (March 2008) | Investor deck | 24 slides | Mar 13, 2008 |
| Arrowhead Research — Investor Presentation (March 2008) | Investor deck | 21 slides | Mar 13, 2008 |
| Technical Presentation | Technical | 14 slides | |
| Technical Presentation | Technical | 26 slides |
Financings
| Raise | Date |
|---|---|
| 0.00% convertible senior notes due 2032 Closed: US$625M raised · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets Use of proceeds: About $42.8 million for capped call transactions; remainder for general corporate purposes incl. R&D, clinical trials and commercial launch preparation | Feb 5, 2026 |
| Public offering of common stock and pre-funded warrants Closed: US$200M raised · US$64.5 a share · Jefferies +4 Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets Use of proceeds: General corporate purposes incl. working capital, R&D, clinical trials and commercial launch preparation; may prepay Sixth Street loans | Feb 5, 2026 |
| Strategic investment of common stock Closed: US$325M raised · US$27.25 a share Buyers: Sarepta ($325 million of Arrowhead common stock at $27.25 per share) | Oct 21, 2025 |
| Strategic investment of common stock Closed: US$325M raised · US$27.25 a share Buyers: Sarepta Therapeutics ($325 million equity investment priced at $27.2507); Sarepta ($325 million of Arrowhead common stock at $27.25 per share) | Feb 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 450.8M | 829.4M | 3.55M | 240.7M | 243.2M | 138.3M | 88.0M | 168.8M | 16.1M | 31.4M |
| Cost of revenue | 23.9M | 18.6M | 12.5M | 10.4M | 67.4M | 63.7M | ||||
| Gross profit | 829.4M | -15.0M | 228.2M | 243.2M | 138.3M | 88.0M | 168.8M | 16.1M | 31.4M | |
| Research and development | 739.1M | 607.2M | 505.9M | 353.2M | 297.3M | 206.3M | 128.9M | 81.0M | 53.0M | 50.9M |
| Selling, general and administrative | 202.0M | 123.9M | 98.8M | 90.9M | 124.4M | 81.0M | 52.3M | 26.6M | 19.1M | 17.5M |
| Operating income | -707.2M | 98.3M | -601.1M | -205.0M | -178.5M | -149.0M | -93.2M | 61.2M | -55.9M | -37.0M |
| Depreciation and amortization | 24.7M | 22.2M | 16.9M | 10.7M | 8.70M | 6.60M | 4.20M | 2.70M | 3.00M | 2.99M |
| EBITDA | -682.5M | 120.5M | -584.2M | -194.3M | -169.8M | -142.4M | -89.0M | 63.9M | -52.9M | -34.0M |
| Interest expense | 93.7M | 89.4M | 32.4M | 18.3M | 0 | 0 | 9.19B | 6.96B | 1.05B | 415.1M |
| Income before tax | -723.9M | 51.5M | -612.5M | -206.5M | -172.7M | -140.8M | -84.6M | 68.1M | -54.4M | -34.4M |
| Income tax | -6.78M | 21.4M | -2.77M | 2.78M | 3.79M | 2.00K | 2.00K | 174.0K | 2.40K | 2.40K |
| Net income | -724.2M | -1.63M | -599.5M | -205.3M | -176.1M | -140.8M | -84.6M | 68.0M | -54.5M | -34.4M |
| Earnings per share, basic | -5.11 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 |
| Earnings per share, diluted | -5.11 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | -0.65 | -0.47 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 62.7M | 226.5M | 102.7M | 110.9M | 108.0M | 184.4M | 143.6M | 221.8M | 30.1M | 24.8M |
| Short-term investments | 1.13B | 692.8M | 578.3M | 292.7M | 0 | 126.7M | 85.0M | 36.9M | 46.4M | 40.8M |
| Receivables | 9.93M | 6.82M | 0 | 0 | 1.41M | 10.3M | 846.0K | 661.4K | 327.4K | 67.8K |
| Inventory | 9.07M | 0 | -21.6M | 4.36M | 4.25M | 3.32M | 1.27M | 867.4K | ||
| Current assets | 1.29B | 950.6M | 695.5M | 416.5M | 405.3M | 384.6M | 322.4M | 265.2M | 78.8M | 67.9M |
| Property, plant and equipment | 371.3M | 382.5M | 386.0M | 290.3M | 110.3M | 48.7M | 30.9M | 23.2M | 13.9M | 15.5M |
| Goodwill | 15.4M | 17.1M | 18.8M | 20.5M | ||||||
| Total assets | 1.74B | 1.39B | 1.14B | 765.6M | 691.9M | 710.1M | 522.5M | 349.8M | 111.6M | 104.0M |
| Accounts payable | 30.1M | 17.7M | 11.4M | 35.9M | 2.87M | 9.46M | 6.83M | 7.65M | 2.81M | 4.08M |
| Current liabilities | 311.3M | 195.5M | 103.2M | 105.5M | 138.8M | 146.5M | 40.7M | 97.1M | 12.4M | 18.7M |
| Long-term debt | 214.9M | 393.2M | 2.10M | 2.33M | ||||||
| Total debt | 366.3M | 851.9M | 383.5M | 81.6M | 25.5M | 21.1M | 2.33M | 2.53M | ||
| Total liabilities | 881.9M | 948.7M | 478.4M | 273.6M | 301.3M | 60.7M | 105.8M | 16.4M | 23.2M | |
| Shareholders' equity | 50.3M | 466.1M | 185.4M | 271.3M | 398.5M | 408.8M | 461.8M | 244.6M | 95.8M | 81.4M |
| Shares outstanding | 141.3M | 135.7M | 124.4M | 107.3M | 106.0M | 104.3M | 102.4M | 95.5M | 88.5M | 74.8M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -271.9M | 179.6M | -462.9M | -153.9M | -136.1M | 171.3M | -95.8M | 173.0M | -47.2M | -23.9M |
| Capital spending | -12.0M | -22.7M | -141.5M | -176.7M | -52.8M | -23.6M | -12.0M | -12.0M | -1.42M | -7.92M |
| Free cash flow | -283.9M | 156.9M | -604.3M | -330.6M | -188.9M | 147.7M | -107.8M | 161.0M | -48.6M | -31.9M |
| Cash from investing | -670.5M | -129.3M | -420.1M | -96.2M | -5.42M | -141.7M | -240.8M | -47.7M | -7.43M | -48.6M |
| Cash from financing | 776.8M | 74.0M | 870.5M | 253.1M | 65.2M | 11.3M | 257.9M | 66.4M | 60.0M | 12.1M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 5.19M | 11.3M | 257.9M | 68.8M | -54.7K | -438.8K | ||||
| Change in cash | -165.6M | 124.3M | -12.4M | 3.01M | -76.4M | 40.9M | -78.2M | 191.7M | 5.29M | -60.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-K · Annual report | Nov 12, 2026 | Annual report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Management or board change | SEC |
| 144/A · Notice of proposed sale, amended | May 19, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | May 19, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | May 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 20, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 5, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Jan 26, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jan 26, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 26, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 8, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 305B2 | Jan 8, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Jan 8, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Jan 7, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 6, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 6, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| S-3ASR · Registration statement | Dec 10, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 28, 2025 | Other filings | SEC |
| 10-K · Annual report | Nov 25, 2025 | Annual report | SEC |
| 8-K · Current report | Nov 25, 2025 | Results | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Oct 10, 2025 | Annual report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 15, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 10, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 15, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 18, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2025 | Other filings | SEC |
| 424B7 · Prospectus | Mar 7, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2025 | Results | SEC |
| 10-Q · Quarterly report | Feb 10, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Feb 6, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jan 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jan 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 424B7 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 17, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Dec 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 26, 2024 | Results | SEC |
| 10-K · Annual report | Nov 26, 2024 | Annual report | SEC |
| 5 · Annual statement of ownership | Nov 15, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 16, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2024 | Other filings | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 2, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Arrowhead Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 141,368,004
- Fully diluted
- 141,564,889
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 141,368,004 | Nov 5, 2026 |
| Options and RSUs | 196,885 | Oct 22, 2026 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 141,368,004 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Douglas S Ingram Other companies: Relay Therapeutics, Inc. (Director · Since at least Jul 15, 2020); Sarepta Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Jun 26, 2017); Endo International PLC (Director · May 5, 2016 – Jun 9, 2017 · Past); Skye Bioscience, Inc. (Vice Chairman, Director · Jun 1, 2015 – Oct 20, 2015 · Past); Volcom Inc (Director · Aug 3, 2006 – Jun 23, 2011 · Past) | Director · Since at least Feb 6, 2025 |
| William Waddill Other companies: Annexon, Inc. (LEAD INDEPENDENT DIRECTOR · Since at least Aug 12, 2021); Protagonist Therapeutics, Inc. (Independent Director · Since at least Aug 10, 2016); Turnstone Biologics Corp. (Director · Apr 15, 2024 – Jun 3, 2024 · Past); Calithera Biosciences, Inc. (SR. VP & CFO · Oct 1, 2014 – Nov 29, 2016 · Past); OncoMed Pharmaceuticals Inc (SVP & Chief Financial Officer · Jul 17, 2013 – Jul 23, 2013 · Past) | Director · Since at least Dec 20, 2017 |
| Adeoye Olukotun Other companies: Tonix Pharmaceuticals Holding Corp. (Director · Since at least Sep 5, 2018); Genesis Unicorn Capital Corp (Chief Executive Officer · Feb 14, 2022 – Feb 14, 2022 · Past); Via Pharmaceuticals Inc (Chief Medical Officer · Aug 2, 2007 – Dec 17, 2007 · Past); Icagen Inc (Director · Aug 3, 2006 – Oct 27, 2011 · Past) | Director · Since at least Sep 1, 2020 |
| Douglas B Given Other companies: Via Pharmaceuticals Inc (Director · Mar 12, 2009 – Nov 15, 2010 · Past); Aksys Ltd (Director · Jun 23, 2006 – Oct 6, 2006 · Past) | Director · Feb 16, 2012 – Dec 16, 2024 · Past |
| Hongbo Lu Other companies: Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Terns Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2024) | Director · Since at least Mar 15, 2024 |
| Marianne De Backer Other companies: Vir Biotechnology, Inc. (PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR · Since at least Apr 3, 2023); Kronos Bio Inc (Director · Jan 25, 2021 – Jun 22, 2023 · Past) | Director · Dec 12, 2019 – Jan 10, 2023 · Past |
| Michael Perry Other companies: Avita Medical, Inc. (Director · Sep 14, 2019 – Nov 21, 2022 · Past); Armata Pharmaceuticals, Inc. (Director · May 8, 2006 – Dec 31, 2019 · Past) | Director · Since at least Dec 22, 2011 |
| Victoria Vakiener Other companies: Chimerix Inc (Director · Apr 22, 2021 – Apr 21, 2025 · Past); Epizyme Inc (Chief Commercial Officer · Sep 18, 2020 – Feb 4, 2021 · Past) | Director · Since at least May 2, 2022 |
| Bruce D Given Other companies: Encysive Pharmaceuticals Inc (President & CEO, Director · Mar 2, 2006 – Mar 14, 2007 · Past) | Chief Operating Officer · Oct 26, 2011 – Apr 27, 2020 · Past |
| Curt Bradshaw Other companies: NeuBase Therapeutics Inc (Chief Scientific Officer · Dec 1, 2020 – Dec 1, 2020 · Past) | Chief Scientific Officer · Nov 18, 2019 – Nov 19, 2020 · Past |
All 29 people
| Person | Seat |
|---|---|
| Edward W Frykman Other companies: Acacia Research Corporation (Director · Jan 3, 2006 – Mar 15, 2017 · Past) | Director · Feb 23, 2006 – Jan 1, 2018 · Past |
| James Hassard Other companies: Crinetics Pharmaceuticals, Inc. (Chief Commercial Officer · Feb 28, 2022 – Jul 5, 2024 · Past) | Chief Commercial Officer · Jan 7, 2021 – Jun 22, 2021 · Past |
| Martin Javier San Other companies: LeonaBio, Inc. (CHIEF MEDICAL OFFICER · Since at least Apr 15, 2024) | Chief Medical Officer · Nov 21, 2022 – Jan 4, 2024 · Past |
| Peter Brian Leone Other companies: Bicycle Therapeutics PLC (Chief Business Officer · May 22, 2019 – May 28, 2019 · Past) | VP, Strategic Bus. Initiatives · Mar 6, 2015 – Oct 19, 2018 · Past |
| Zhen Li Other companies: ADARx Pharmaceuticals, Inc. (President & CEO · Since at least Sep 24, 2026) | Snr. VP, Chem and Non-Clin Dev · Jan 25, 2018 – Jan 14, 2019 · Past |
| Christopher Anzalone | President, CEO and Chairman of the Board · Since at least Dec 1, 2007 |
| Daniel Apel | Chief Financial Officer · Since at least Apr 15, 2025 |
| David L Lewis | Chief Scientific Officer · Jan 2, 2014 – Jan 1, 2016 · Past |
| Edward Lee Jacobs | Subsidiary CEO · Jan 1, 2007 – Jan 1, 2007 · Past |
| James Hamilton | Chief Medical Officer, Head of R&D · Since at least Jan 12, 2024 |
| Joseph Theodore Kingsley III | Chief Financial Officer · May 26, 2006 – Mar 29, 2007 · Past |
| Kenneth Allen Myszkowski | Chief Financial Officer · Oct 20, 2020 – Jan 4, 2025 · Past |
| Matt Cohen | Board Member · Since at least Jun 17, 2026 |
| Matthew Gregory Cohen | Director · Since at least Jun 15, 2026 |
| Mauro Ferrari | Director · Since at least Aug 18, 2010 |
| Oye Olukotun | Director · Since at least Nov 5, 2026 |
| Patrick O’Brien | Chief Operating Officer · Since at least May 28, 2019 |
| Tao Pei | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Tracie Oliver | Chief Commercial Officer · Jun 20, 2022 – Jul 2, 2024 · Past |
Log in to ask 6ix AI your own questions about Arrowhead Pharmaceuticals, Inc.